edotreotide has been researched along with Neoplasms in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 13 (72.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Cortés Romera, M; Guerrero-Pérez, F; Herrera-Martínez, Y; Martín-Marcuartu, JJ; Telué Vega, A; Vercher-Conejero, JL | 1 |
| Antoch, G; Bruckmann, NM; Herrmann, K; Ingenwerth, M; Kirchner, J; Lahner, H; Rischpler, C; Sawicki, LM; Theurer, S; Umutlu, L | 1 |
| Abolmaali, ND; Abramyuk, AM; Tokalov, SV; Zophel, K | 1 |
| Besse, IM; Bushnell, DL; Juweid, ME; Madsen, MT | 1 |
| Endo, K; Hanaoka, H; Higuchi, T; Iida, Y; Oriuchi, N; Paudyal, B; Paudyal, P; Tominaga, H; Watanabe, S; Yamada, K | 1 |
| Hughey, BJ; Klinkowstein, RE; Laforest, R; Lewis, MR; Margenau, WH; Reichert, DE; Shefer, RE; Welch, MJ | 1 |
| Bartolomei, M; Bodei, L; Caracciolo, M; Chinol, M; Cremonesi, M; Grana, C; Mäcke, HR; Paganelli, G; Rocca, P; Zoboli, S | 1 |
| Anderson, T; Atcher, R; Nayak, T; Norenberg, J | 1 |
| Ginj, M; Hinni, K; Maecke, HR; Schulz, S; Tschumi, S | 1 |
| Albert, R; Bruns, C; Knecht, H; Pless, J; Simeon, C; Smith-Jones, P; Stolz, B | 1 |
| Behe, M; Heppeler, A; Herrmann, R; Jermann, E; Maecke, HR; Muller, J; Otte, A; Powell, P | 1 |
| Chinol, M; Cremonesi, M; Mäcke, HR; Paganelli, G; Zoboli, S | 1 |
| Bakker, W; Chen, T; Jamar, F; Krenning, E; Kvols, L; Liu, J; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Yeh, CM | 1 |
| de Jong, M; Krenning, EP; Kwekkeboom, D | 1 |
| Bartolomei, M; Chinol, M; Cremonesi, M; Ferrari, M; Fiorenza, M; Paganelli, G; Sacco, E; Stabin, MG; Tosi, G | 1 |
| Bartolomei, M; Bodei, L; Chinol, M; Cremonesi, M; de Braud, F; De Cicco, C; Ferrari, M; Grana, C; Mäcke, HR; Orsi, F; Paganelli, G; Zoboli, S | 1 |
| Arnold, R; Becker, W; Béhé, M; Behr, TM; Goldenberg, DM; Gotthardt, M; Gratz, S; Kluge, G; Schipper, ML | 1 |
| Bodei, L; Chinol, M; Cremonesi, M; Paganelli, G | 1 |
2 review(s) available for edotreotide and Neoplasms
| Article | Year |
|---|---|
OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy.
Topics: Animals; Breast Neoplasms; Carcinoma, Small Cell; Dose-Response Relationship, Radiation; Female; Humans; Indium Radioisotopes; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasms; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes | 2000 |
Peptide receptor imaging and therapy.
Topics: Humans; Indium Radioisotopes; Neoplasms; Neuroendocrine Tumors; Octreotide; Oligopeptides; Pentetic Acid; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes | 2000 |
4 trial(s) available for edotreotide and Neoplasms
| Article | Year |
|---|---|
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.
Topics: Adult; Aged; Amino Acids; Biomarkers, Tumor; Blood Platelets; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Hemoglobins; Humans; Kidney; Lymphocytes; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Octreotide; Radiation-Protective Agents; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Renal Insufficiency; Vomiting; Yttrium Radioisotopes | 2003 |
Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients.
Topics: Adult; Aged; Female; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed; Yttrium Radioisotopes | 1999 |
Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide.
Topics: Adult; Aged; Female; Humans; Indicators and Reagents; Male; Middle Aged; Neoplasms; Octreotide; Radiometry; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Tissue Distribution; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2001 |
Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Neoplasms; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes | 2002 |
12 other study(ies) available for edotreotide and Neoplasms
| Article | Year |
|---|---|
[
Topics: Gallium Radioisotopes; Humans; Neoplasms; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Correlation between contrast enhancement, standardized uptake value (SUV), and diffusion restriction (ADC) with tumor grading in patients with therapy-naive neuroendocrine neoplasms using hybrid
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasm Grading; Neoplasms; Octreotide; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals | 2021 |
Retrospective analysis of radiation load during examination of cancer patients by (68)Ga-DOTATOC and (18)F-FDG positron emission tomography.
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gadolinium; Humans; Neoplasms; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radiation Dosage; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2008 |
Modeling combined radiopharmaceutical therapy: a linear optimization framework.
Topics: 3-Iodobenzylguanidine; Humans; Models, Theoretical; Neoplasms; Octreotide; Radiation Dosage; Radiopharmaceuticals | 2009 |
Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
Topics: Animals; Cell Line, Tumor; Copper Radioisotopes; Gene Expression Regulation, Neoplastic; Humans; Isotope Labeling; Mice; Neoplasms; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Receptors, Somatostatin; Tissue Distribution | 2009 |
Production and purification of gallium-66 for preparation of tumor-targeting radiopharmaceuticals.
Topics: Biotin; Gallium Radioisotopes; Humans; Isotope Labeling; Neoplasms; Octreotide; Organometallic Compounds; Radionuclide Imaging; Radiopharmaceuticals; Zinc Isotopes | 2002 |
A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
Topics: Actinium; Alpha Particles; Apoptosis; Beta Particles; Bismuth; Cell Line, Tumor; Cell Nucleus; Cell Survival; Dose-Response Relationship, Radiation; Energy Transfer; Enzyme-Linked Immunosorbent Assay; Humans; Ligands; Lutetium; Mitosis; Models, Statistical; Neoplasms; Octreotide; Radioisotopes; Radiometry; Radiopharmaceuticals; Receptors, Somatostatin | 2005 |
Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters.
Topics: Cell Line; Cell Nucleus; Electrons; Humans; Indium Radioisotopes; Kinetics; Neoplasms; Octreotide; Peptides; Protein Structure, Tertiary; Radioisotopes; Radiotherapy; Receptors, G-Protein-Coupled; Somatostatin; Time Factors; Transfection | 2005 |
Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1,Tyr3]-octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man.
Topics: Drug Carriers; Heterocyclic Compounds, 1-Ring; Humans; Indicators and Reagents; Iodine Radioisotopes; Neoplasms; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes | 1998 |
Yttrium-90 DOTATOC: first clinical results.
Topics: Adult; Aged; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Neoplasms; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes | 1999 |
Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience.
Topics: Humans; Indium Radioisotopes; Neoplasms; Octreotide; Radioimmunotherapy; Radiopharmaceuticals; Radiotherapy Dosage; Yttrium Radioisotopes | 2000 |
Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis.
Topics: Animals; Humans; Kidney; Neoplasms; Octreotide; Peptides; Radiopharmaceuticals; Radiotherapy Dosage; Yttrium Radioisotopes | 2002 |